Alpha 2.0
Login Register
» Articles » PMID: 32479986

Type 3 Hypersensitivity in COVID-19 Vasculitis

Overview
Journal Clin Immunol
Specialty Allergy & Immunology
Date 2020 Jun 2
PMID 32479986
Citations 83
Authors
Luca Roncati
Giulia Ligabue
Luca Fabbiani
Claudia Malagoli
Graziana Gallo
Beatrice Lusenti
Vincenzo Nasillo
Antonio Manenti
Antonio Maiorana
Affiliations
Soon will be listed here.
Abstract

Coronavirus Disease 2019 (COVID-19) is an ongoing public health emergency and new knowledge about its immunopathogenic mechanisms is deemed necessary in the attempt to reduce the death burden, globally. For the first time in worldwide literature, we provide scientific evidence that in COVID-19 vasculitis a life-threatening escalation from type 2 T-helper immune response (humoral immunity) to type 3 hypersensitivity (immune complex disease) takes place. The subsequent deposition of immune complexes inside the vascular walls is supposed to induce a severe inflammatory state and a cytokine release syndrome, whose interleukin-6 is the key myokine, from the smooth muscle cells of blood vessels.

Citing Articles

Coronary Implications of COVID-19.

Triantafyllis A, Sfantou D, Karapedi E, Peteinaki K, Kotoulas S, Saad R Med Princ Pract. 2024; 34(1):1-12.

PMID: 39307131 PMC: 11805551. DOI: 10.1159/000541553.

Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations.

Starshinova A, Borozinets A, Kulpina A, Sereda V, Rubinstein A, Kudryavtsev I Pathophysiology. 2024; 31(2):269-287.

PMID: 38921725 PMC: 11206645. DOI: 10.3390/pathophysiology31020020.

Ultramicronized Palmitoylethanolamide and Luteolin: Drug Candidates in Post-COVID-19 Critical Illness Neuropathy and Positioning-Related Peripheral Nerve Injury of the Upper Extremity.

Roncati L, Marra C, Gravina D, Di Massa G, Della Rosa N, Adani R J Hand Microsurg. 2024; 16(2):100028.

PMID: 38855524 PMC: 11144630. DOI: 10.1055/s-0043-1764161.

IgA vasculitis after COVID-19: a case-based review.

Suszek D, Grzywa-Celinska A, Emeryk-Maksymiuk J, Krusinski A, Redestowicz K, Siwiec J Rheumatol Int. 2024; 44(7):1353-1357.

PMID: 38739223 PMC: 11178596. DOI: 10.1007/s00296-024-05606-4.

Small Molecules for the Treatment of Long-COVID-Related Vascular Damage and Abnormal Blood Clotting: A Patent-Based Appraisal.

Samarelli F, Graziano G, Gambacorta N, Graps E, Leonetti F, Nicolotti O Viruses. 2024; 16(3).

PMID: 38543815 PMC: 10976273. DOI: 10.3390/v16030450.

References
1.
Roncati L, Nasillo V, Lusenti B, Riva G . Signals of T2 immune response from COVID-19 patients requiring intensive care. Ann Hematol. 2020; 99(6):1419-1420. PMC: 7205481. DOI: 10.1007/s00277-020-04066-7. View
2.
Mastaglio S, Ruggeri A, Risitano A, Angelillo P, Yancopoulou D, Mastellos D . The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020; 215:108450. PMC: 7189192. DOI: 10.1016/j.clim.2020.108450. View
3.
Guillevin L, Dorner T . Vasculitis: mechanisms involved and clinical manifestations. Arthritis Res Ther. 2007; 9 Suppl 2:S9. PMC: 2072881. DOI: 10.1186/ar2193. View
4.
Roncati L, Palmieri B . What about the original antigenic sin of the humans versus SARS-CoV-2?. Med Hypotheses. 2020; 142:109824. PMC: 7204740. DOI: 10.1016/j.mehy.2020.109824. View
5.
Roncati L, Gallo G, Manenti A, Palmieri B . Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2. Med Hypotheses. 2020; 140:109686. PMC: 7118521. DOI: 10.1016/j.mehy.2020.109686. View